Johnson & Johnson and it subsidiary Janssen Pharmaceuticals were pleased to hear the results of the Jan. 28 ruling that overturned the large judgment against them based on allegations that they violated Louisiana’s Medical Assistance Programs Integrity Law (MAPIL) by misrepresenting the potential risks and side effects of the anti-psychotic drug Risperdal through off-label statements….
News-At-A-Glance: Louisiana Supreme Court Reverses $330 Million Judgment
by 1149700977@qq.com | Feb 23, 2015 | Lab Compliance Advisor | 0 comments